Orientations
COVID-19 Vaccine Explainer - COVID-19 Vaccine Janssen (Ad26.COV2-S [recombinant]) - UPDATED JULY 2022
The COVID-19 Vaccine Janssen (Ad26.COV2-S [recombinant]) is a non-replicating adenoviral vector vaccine against coronavirus disease 2019 (COVID-19). The vector virus contained within the vaccine delivers an instruction to host cells to produce the SARS-CoV-2 antigen called the spike protein, which triggers the production of antibodies. This allows the body to generate an immune response and to retain that information in memory immune cells. Efficacy shown in clinical trials in participants who received a single dose of COVID-19 Vaccine Janssen was 66.9% against symptomatic SARS-CoV-2 infection, 76.7% against severe COVID-19 after 14 days and 85.4% after 28 days, and 93.1% against hospitalizations. The data reviewed at this time support the conclusion that the known and potential benefits of COVID-19 Vaccine Janssen outweigh the known and potential risks.
Auteurs
Langues
- Anglais
Année de publication
2021
Type
Orientations
Catégories
- Vaccins et dispositifs d'administration
Maladies
- COVID-19
Organisations
- Organisation Mondiale de la Santé (OMS)
Critère GEV
- E8 Gestion des vaccins
